897 related articles for article (PubMed ID: 29936529)
1. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
[TBL] [Abstract][Full Text] [Related]
2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Hypoglycemia and Safety Outcomes With Long-Acting Insulins Versus Insulin NPH in Pregestational and Gestational Diabetes.
Sleeman A; Odom J; Schellinger M
Ann Pharmacother; 2020 Jul; 54(7):669-675. PubMed ID: 31893932
[No Abstract] [Full Text] [Related]
4. Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin.
Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Muthuri S; Wernecke M; MaCurdy TE; Kelman JA; Graham DJ
JAMA Intern Med; 2021 May; 181(5):598-607. PubMed ID: 33646277
[TBL] [Abstract][Full Text] [Related]
5. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
[TBL] [Abstract][Full Text] [Related]
7. Basal Insulin Analogs versus Neutral Protamine Hagedorn for Type 2 Diabetics.
Fishel Bartal M; Ward C; Refuerzo JS; Ashimi SS; Joycelyn CA; Chen HY; Chauhan SP; Sibai BM
Am J Perinatol; 2020 Jan; 37(1):30-36. PubMed ID: 31430822
[TBL] [Abstract][Full Text] [Related]
8. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
Strandberg AY; Khanfir H; Mäkimattila S; Saukkonen T; Strandberg TE; Hoti F
Ann Med; 2017 Jun; 49(4):357-364. PubMed ID: 28042719
[TBL] [Abstract][Full Text] [Related]
9. Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials.
Porcellati F; Lin J; Lucidi P; Bolli GB; Fanelli CG
Medicine (Baltimore); 2017 Feb; 96(5):e6022. PubMed ID: 28151905
[TBL] [Abstract][Full Text] [Related]
10. Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors.
Zhang T; Ji L; Gao Y; Zhang P; Zhu D; Li X; Ji J; Zhao F; Zhang H; Guo X
Diabetes Technol Ther; 2017 Nov; 19(11):675-684. PubMed ID: 29090977
[TBL] [Abstract][Full Text] [Related]
11. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and safety of different basal insulins in a real-world setting.
Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
[TBL] [Abstract][Full Text] [Related]
13. A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.
Idris I; Gordon J; Tilling C; Vora J
J Med Econ; 2015 Apr; 18(4):273-82. PubMed ID: 25422990
[TBL] [Abstract][Full Text] [Related]
14. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
15. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
16. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
Duckworth W; Davis SN
J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
[TBL] [Abstract][Full Text] [Related]
17. Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction.
Berard L; Cameron B; Woo V; Stewart J
Can J Diabetes; 2015 Aug; 39(4):296-301. PubMed ID: 25819531
[TBL] [Abstract][Full Text] [Related]
18. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
Garber AJ; Clauson P; Pedersen CB; Kølendorf K
J Am Geriatr Soc; 2007 Nov; 55(11):1735-40. PubMed ID: 17979896
[TBL] [Abstract][Full Text] [Related]
19. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
[TBL] [Abstract][Full Text] [Related]
20. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
